Fig. 1: FBXO22 expression is upregulated in cervical cancer and correlated with neoplastic progression and survival of CC patients.

A The expression of FBXO22 mRNA in human cervical cancers and corresponding normal cervical tissues from GEPIA database. CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma. *P < 0.05. B Representative images of Western blotting analysis of the FBXO22 protein level in tumor-adjacent cervical tissues (N) and cervical cancer tissues (T) of 5 CC patients (left panel) and the relative expression of FBXO22 protein is presented as normalized band density to the corresponding GAPDH band density (right panel). **P < 0.01. Data are expressed as mean ± SEM (N = 5). C Representative images of IHC staining with anti-FBXO22 antibody from cervical cancer (CC) tissues and adjacent cervical epithelial tissues in a human CC tissue microarray (×40 and ×200, magnification). D Scores of IHC staining are presented. ***P < 0.001. Data are expressed as mean ± SEM. E Representative images of IHC staining with anti-FBXO22 antibody in human normal cervical tissues (NC), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and squamous cell carcinoma (SCC) (×400, magnification). F Histogram of FBXO22 protein expression in NC, squamous intraepithelial lesion (SIL), and SCC. G, H Kaplan–Meier analysis of G disease-free survival (DFS) and H overall survival (OS) of cervical cancer patients related to the levels of FBXO22 protein.